End Price Gouging for Medications Act

This bill sets annual reference prices for prescription drugs based on the lowest prices in specific countries (like Canada, UK, and Germany), preventing manufacturers from charging more than this price for drugs covered under major federal health programs. It directly affects Medicare, Medicaid, VA care, TRICARE, and other federal health programs by capping drug costs at the reference price. Manufacturers must sell drugs at or below this reference price to all patients, including those without insurance, with civil penalties of up to five times the revenue difference for non-compliance. Collected penalties fund drug research through the National Institutes of Health.